NewLink Genetics (NASDAQ:NLNK) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of NewLink Genetics (NASDAQ:NLNK) from a buy rating to a hold rating in a report published on Wednesday morning, Zacks.com reports.

According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “

Separately, ValuEngine lowered shares of Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating and three have given a hold rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $3.75.

NewLink Genetics stock opened at $1.46 on Wednesday. The firm has a market capitalization of $54.43 million, a PE ratio of -1.01 and a beta of 1.36. NewLink Genetics has a twelve month low of $1.28 and a twelve month high of $4.95. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.33 and a quick ratio of 13.33. The firm has a 50 day moving average of $1.60.

NewLink Genetics (NASDAQ:NLNK) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.04. The company had revenue of $0.11 million during the quarter. NewLink Genetics had a negative net margin of 1,691.08% and a negative return on equity of 38.63%. On average, equities research analysts forecast that NewLink Genetics will post -0.1 EPS for the current fiscal year.

Hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC lifted its position in shares of NewLink Genetics by 25.7% in the first quarter. Acadian Asset Management LLC now owns 404,083 shares of the biotechnology company’s stock worth $780,000 after purchasing an additional 82,579 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of NewLink Genetics by 22.6% in the fourth quarter. Two Sigma Advisers LP now owns 110,000 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 20,300 shares in the last quarter. Paloma Partners Management Co bought a new stake in shares of NewLink Genetics in the fourth quarter worth $30,000. Pennsylvania Trust Co bought a new stake in shares of NewLink Genetics in the first quarter worth $48,000. Finally, Virtu Financial LLC bought a new stake in shares of NewLink Genetics in the first quarter worth $60,000. 34.30% of the stock is currently owned by institutional investors and hedge funds.

NewLink Genetics Company Profile

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.

Featured Article: What Is An Exchange-Traded Fund (ETF)?

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit